Malignant Mesothelioma Epidemiology Market Analysis | 2021-2026

Market Insights

The malignant mesothelioma epidemiology market was estimated at USD 380.2 million in 2020 and is likely to grow at a CAGR of 6.2% during 2021-2026 to reach USD 540.8 million by 2026.

Want to know more about the market scope? Register Here

Market Dynamics

Introduction

Malignant mesothelioma is known as rare cancer that originates from the inner lining of the body’s serous cavities i.e., peritoneum, pleura, pericardium, and vaginal tunic of the testicle. It is caused due to asbestos exposure which can be hidden in the living area or any other object such as curtains, cardboard, toys, and board covers among others.

COVID-19 Impact 

The covid-19 outbreak posed significant challenges to the healthcare system across geographies. It affected the growth of the malignant mesothelioma epidemiology market negatively as patients postponed their treatment due to a rapid surge in COVID-19 cases across geographies. Also, supply chain disruptions due to the imposition of the lockdown affected the installation of equipment in the hospital and thus, affected the market growth.

Market Drivers

The growth of the global malignant mesothelioma epidemiology market is primarily driven by increasing cases of mesothelioma cancer due to asbestos exposure.

• Millions of people around the world are exposed to asbestos. Additionally, the rising geriatric populace across geographies is expected to add to the market growth substantially.
• Furthermore, the growing emphasis on the development of more advanced cancer treatment methods is likely to drive the market growth at a significant rate during the review period.

Want to have a closer look at this market report? Click Here

Key Players

The following are the key players in the malignant mesothelioma epidemiology market:

• AstraZeneca plc (UK),
• Bristol-Myers Squibb Company (The U.S),
• C.H. Boehringer Sohn AG & Ko. KG (Germany),
• Eli Lilly and Company (The U.S),
• F. Hoffmann-La Roche AG (Switzerland),
• Fresenius Kabi AG (Germany) and
• Mylan N.V. (The U.S),
• Merck & Co., Inc. (The U.S),
• Novartis International AG (Switzerland),
• Pfizer Inc. (The U.S),
• Sanofi S.A. (France),
• Sun Pharmaceuticals Industries Ltd (India). 
• Teva Pharmaceutical Industries Ltd (Israel),

Note: The above list does not necessarily include all the top players in the market.

Are you the leading player in this market? We would love to include your name. Write to us at [email protected]​

Segment Analysis

By Drug Type

"Pemetrexed segment accounted for the largest market share in 2020"

• The market has been segmented based on drug type into pemetrexed, cisplatin, carboplatin, gemcitabine, vinorelbine, and others.
• The pemetrexed segment accounted for the largest market share in 2020 and is expected to register significant growth over the forecast period.
• The segment growth can be attributed to the increasing use of pemetrexed drugs in combination with other drugs.

Regional Analysis

"North America accounted for the largest market share in 2020"

• Geographically, the market in North America accounted for the largest market share in 2020 and is expected to continue its dominance over the forecast period owing to the increasing incidence of cancer disease.
• Additionally, high spending on R&D activities to develop advanced therapies to treat cancer is likely to add to the market growth significantly.
• The market in Asia-Pacific is expected to register a healthy CAGR during the review period on account of the increasing prevalence of cancer and raising awareness about the available cancer treatment methods.

Know the high-growth countries in this report. Register Here

Research Methodology

• This strategic assessment report, from Stratview Research, provides a comprehensive analysis that reflects today’s malignant mesothelioma epidemiology market realities and future market possibilities for the forecast period.
• The report segments and analyzes the market in the most detailed manner to provide a panoramic view of the market.
• The vital data/information provided in the report can play a crucial role for market participants as well as investors in the identification of the low-hanging fruits available in the market as well as to formulate growth strategies to expedite their growth process.
• This report offers high-quality insights and is the outcome of a detailed research methodology comprising extensive secondary research, rigorous primary interviews with industry stakeholders, and validation and triangulation with Stratview Research’s internal database and statistical tools.
• More than 1,000 authenticated secondary sources, such as company annual reports, fact books, press releases, journals, investor presentations, white papers, patents, and articles, have been leveraged to gather the data.
• We conducted more than 15 detailed primary interviews with market players across the value chain in all four regions and industry experts to obtain both qualitative and quantitative insights.

Report Features

This report provides market intelligence in the most comprehensive way. The report structure has been kept such that it offers maximum business value. It provides critical insights into market dynamics and will enable strategic decision-making for existing market players as well as those willing to enter the market. The following are the key features of the report:

• Market structure: Overview, industry life cycle analysis, supply chain analysis.
• Market environment analysis: Growth drivers and constraints, Porter’s five forces analysis, SWOT analysis.
• Market trend and forecast analysis.
• Market segment trend and forecast.
• Competitive landscape and dynamics: Market share, Service portfolio, New Product Launches, etc.
• COVID-19 impact and its recovery curve
• Attractive market segments and associated growth opportunities.
• Emerging trends.
• Strategic growth opportunities for the existing and new players.
• Key success factors.

Market Segmentation

This report studies the market covering 12 years of trend and forecast. The report provides detailed insights into the market dynamics to enable informed business decision-making and growth strategy formulation based on the opportunities present in the market.

The malignant mesothelioma epidemiology market is segmented into the following categories:

 By Type 

• Malignant Pleural Mesothelioma
• Malignant Peritoneal Mesothelioma
• Malignant Pericardial Mesothelioma

By Drug Type 

• Pemetrexed
• Cisplatin
• Carboplatin
• Gemcitabine
• Vinorelbine
• Others

By Route of Administration Type

• Oral
• Parenteral

By Distribution Channel Type

• Hospital Pharmacies
• Retail Pharmacies
• Oncology Centers

By Region

• North America (Country Analysis: The USA, Canada, and Mexico)
• Europe (Country Analysis: Germany, France, The UK, Russia, and the Rest of Europe)
• Asia-Pacific (Country Analysis: China, India, Australia, South Korea, and the Rest of Asia-Pacific)
• Rest of the World (Country Analysis: Saudi Arabia, Brazil, and Others)

Click Here, to learn the market segmentation details.

Customization Options

With this detailed report, Stratview Research offers one of the following free customization options to our respectable clients:

Company Profiling

• Detailed profiling of additional market players (up to three players)
• SWOT analysis of key players (up to three players)

Competitive Benchmarking

• Benchmarking of key players on the following parameters: Product portfolio, geographical reach, regional presence, and strategic alliances.

Custom Research:

Stratview research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry to [email protected].